MAP2K7 and renal cell carcinoma: Combination studies with cabozantinib need to be considered, and our data suggest that either dasatinib or a MEK inhibitor would be suitable (e.g., cobimetinib, since it is undergoing combination studies in RCC [+azetolizumab, NCT03264066]).